Puthucheary ZA, Rawal J, McPhail M, et al
Diabetes Care 2016;39(8):13451355
Finally, it needs to be re-emphasised that, in all insulin-treated people with type 2 diabetes, agents associated with cardiorenal protection or weight reduction should be kept in the treatment regimen whenever possible [331]
The following individual and combined search terms were used: GLP-1, Semaglutide and Liraglutide, molecular mechanism, lipid metabolism, insulin metabolism, glucose homeostasis, energy expenditure obesity treatment, type 2 diabetes mellitus, side effects, clinical trials, treatment option, fatty liver disease, hypertension, neurodegenerative diseases, cardiovascular diseases, therapeutic options. Only articles published in the last 10 years are included, although older pivotal studies were added